Gene Therapy Advances Will Unlock Neurodegenerative Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 9 Analysts
Published
17 May 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
US$28.93
87.1% undervalued intrinsic discount15 Aug
US$3.73
1Y
-42.3%7D
18.8%